-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Medline, Lowers Price Target to $46

Benzinga·08/06/2026 17:39:11
Listen to the news
RBC Capital analyst Ryan Halsted maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $53 to $46.